EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Monoamine–Glutamate Continuum of Depression: A Neurobiological Framework for Precision Psychiatry

Pietro Carmellini iD, Alessandro Cuomo, Maria Beatrice Rescalli iD, Mario Pinzi iD, Afendra Dourmas, Andrea Fagiolini iD

Pharmaceuticals · 24.04.2026 · 19 (5) · 662

DOI: 10.3390/ph19050662 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 24.04.2026. Verfasst von Pietro Carmellini und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Developmental Medicine, Division of Psychiatry, School of Medicine, University of Siena, 53100 Siena, Italy. Die Arbeit nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union’s Horizon Europe, European Union.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Major depressive disorder (MDD) remains a leading cause of disability worldwide and exhibits substantial biological heterogeneity that is not adequately captured by current symptom-based diagnostic systems. While the classical monoamine hypothesis has historically guided antidepressant development, it does not fully account for variability in treatment response, delayed therapeutic onset, or the persistence of cognitive and anhedonic symptoms. Converging evidence from molecular, neuroimaging, and translational studies increasingly implicates glutamatergic dysregulation and impaired neuroplasticity as key mechanisms in depressive pathology. This narrative review aims to integrate monoaminergic and glutamatergic perspectives within a dimensional framework that may help explain clinical heterogeneity and inform mechanism-based treatment strategies.

Methods

A narrative synthesis of the literature was conducted using major biomedical databases including PubMed, Scopus, and Web of Science. Preclinical studies, neuroimaging investigations, biomarker research, randomized clinical trials, and meta-analyses examining monoaminergic dysfunction, glutamatergic signaling, neuroplasticity pathways, and rapid-acting antidepressants were reviewed and thematically integrated.

Results

Evidence indicates that depressive syndromes may reflect varying contributions of monoaminergic dysregulation and glutamatergic–neuroplastic impairment. Monoaminergic disturbances interact with inflammatory and neuroendocrine processes, including cytokine-driven activation of the kynurenine pathway. In parallel, alterations in glutamatergic signaling, glial function, and BDNF–TrkB–mTOR pathways contribute to synaptic atrophy and network dysfunction. Rapid-acting antidepressants such as ketamine, esketamine, and dextromethorphan–bupropion provide clinical proof-of-concept that direct engagement of synaptic plasticity mechanisms can accelerate symptom improvement, particularly in treatment-resistant depression.

Conclusions

Integrating monoaminergic and glutamatergic mechanisms within a “monoamine–glutamate continuum” offers a conceptual framework for understanding depressive heterogeneity and treatment response. Multimodal approaches combining clinical phenotyping with inflammatory, neuroimaging, and molecular markers may ultimately support mechanism-informed precision psychiatry strategies in major depressive disorder.

Schlagwörter

Stichwörter der Autor:innen

biomarkersglutamate neurotransmissionketaminemajor depressive disordermonoamine hypothesisneurobiological subtypesprecision psychiatryrapid-acting antidepressantssynaptic plasticity

Autor:innen und Institutionen

  • Department of Molecular and Developmental Medicine, Division of Psychiatry, School of Medicine, University of Siena, 53100 Siena, Italy.

ORCID-Profile: Pietro Carmellini, Maria Beatrice Rescalli, Mario Pinzi, Andrea Fagiolini

Förderung

  • European Union’s Horizon Europe
  • European Union

Zitieren

APA

Carmellini, P., Cuomo, A., Rescalli, M. B., Pinzi, M., Dourmas, A., & Fagiolini, A. (2026). The Monoamine–Glutamate Continuum of Depression: A Neurobiological Framework for Precision Psychiatry. Pharmaceuticals, 19(5), 662. https://doi.org/10.3390/ph19050662

Vancouver

Carmellini P, Cuomo A, Rescalli MB, Pinzi M, Dourmas A, Fagiolini A. The Monoamine–Glutamate Continuum of Depression: A Neurobiological Framework for Precision Psychiatry. Pharmaceuticals. 2026;19(5):662. doi:10.3390/ph19050662

BibTeX
@article{Carmellini2026,
  author = {Carmellini, Pietro and Cuomo, Alessandro and Rescalli, Maria Beatrice and Pinzi, Mario and Dourmas, Afendra and Fagiolini, Andrea},
  title = {The Monoamine–Glutamate Continuum of Depression: A Neurobiological Framework for Precision Psychiatry},
  journal = {Pharmaceuticals},
  year = {2026},
  volume = {19},
  number = {5},
  pages = {662},
  doi = {10.3390/ph19050662}
}
Kostenlos starten →